Sebastian Hofbauer
@drhofbauer.bsky.social
Urologist | Charité | Berlin
Reposted by Sebastian Hofbauer
Reposted by Sebastian Hofbauer
Roses are red
Violets are blue
Violets are blue
March 20, 2025 at 5:43 PM
Roses are red
Violets are blue
Violets are blue
Reposted by Sebastian Hofbauer
Die US-Botschaft in Wien muss - wie alle US-Botschaften weltweit - ihr New York Times-Abo kündigen. Und alle Abos des Economist, von Politico, Bloomberg News, Associated Press und Reuters.
Macht Diplomat·innen sicher besser, wenn sie schlechter informiert sind. 😵💫😵💫😵💫
Macht Diplomat·innen sicher besser, wenn sie schlechter informiert sind. 😵💫😵💫😵💫
February 19, 2025 at 2:37 PM
Die US-Botschaft in Wien muss - wie alle US-Botschaften weltweit - ihr New York Times-Abo kündigen. Und alle Abos des Economist, von Politico, Bloomberg News, Associated Press und Reuters.
Macht Diplomat·innen sicher besser, wenn sie schlechter informiert sind. 😵💫😵💫😵💫
Macht Diplomat·innen sicher besser, wenn sie schlechter informiert sind. 😵💫😵💫😵💫
Reposted by Sebastian Hofbauer
Reposted by Sebastian Hofbauer
Reposted by Sebastian Hofbauer
Democracy dies in plain sight.
January 22, 2025 at 5:50 PM
Democracy dies in plain sight.
Reposted by Sebastian Hofbauer
The thing is, I feel like if someone truly, accidentally, & unintentionally made a n*zi salute on a national stage, they would be appropriately horrified by it and apologize. And when they don’t ….. it says everything.
January 22, 2025 at 3:42 AM
The thing is, I feel like if someone truly, accidentally, & unintentionally made a n*zi salute on a national stage, they would be appropriately horrified by it and apologize. And when they don’t ….. it says everything.
Reposted by Sebastian Hofbauer
Just made a donation to Wikipedia. I encourage you to do the same if you can
donate.wikimedia.org/w/index.php
donate.wikimedia.org/w/index.php
January 21, 2025 at 9:44 PM
Just made a donation to Wikipedia. I encourage you to do the same if you can
donate.wikimedia.org/w/index.php
donate.wikimedia.org/w/index.php
Reposted by Sebastian Hofbauer
You’re off Twitter. Good. You’re on your way off IG. Great. Now getting off Amazon… that one’s gonna be tougher. But let’s see if we can do it.
You don’t want to tell your grandkids trust you frolicked in the gardens outside the camp.
You don’t want to tell your grandkids trust you frolicked in the gardens outside the camp.
January 21, 2025 at 12:33 AM
You’re off Twitter. Good. You’re on your way off IG. Great. Now getting off Amazon… that one’s gonna be tougher. But let’s see if we can do it.
You don’t want to tell your grandkids trust you frolicked in the gardens outside the camp.
You don’t want to tell your grandkids trust you frolicked in the gardens outside the camp.
Reposted by Sebastian Hofbauer
#CREST trial with positive results for #PD-1 in HR #NMIBC!
✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC.
✅The study met its primary endpoint with significant improvement of EFS
pfizer.com/news/press-rel…
@oncodaily.bsky.social
✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC.
✅The study met its primary endpoint with significant improvement of EFS
pfizer.com/news/press-rel…
@oncodaily.bsky.social
https://pfizer.com/news/press-rel…
January 11, 2025 at 8:59 AM
#CREST trial with positive results for #PD-1 in HR #NMIBC!
✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC.
✅The study met its primary endpoint with significant improvement of EFS
pfizer.com/news/press-rel…
@oncodaily.bsky.social
✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC.
✅The study met its primary endpoint with significant improvement of EFS
pfizer.com/news/press-rel…
@oncodaily.bsky.social
Reposted by Sebastian Hofbauer
ASCO Publications
ascopubs.org
December 19, 2024 at 6:28 AM
Reposted by Sebastian Hofbauer
Impressive results: Ph 2 trial: BCG + gemcitabine in BCG-exposed #NMIBC (HG Ta/T1/CIS)
✅ 6 & 12 mo CR: 94% & 81%
✅ 6, 12 & 18 mo HG-RFS: 97%, 85%, 76%
✅ 2 Gr AEs (UTI, pneumonitis). No Gr 4,5 AEs
Phase 3 trial vs BCG will follow #SUO24 #BladderCancer @oncodaily.bsky.social
✅ 6 & 12 mo CR: 94% & 81%
✅ 6, 12 & 18 mo HG-RFS: 97%, 85%, 76%
✅ 2 Gr AEs (UTI, pneumonitis). No Gr 4,5 AEs
Phase 3 trial vs BCG will follow #SUO24 #BladderCancer @oncodaily.bsky.social
December 6, 2024 at 11:55 PM
Impressive results: Ph 2 trial: BCG + gemcitabine in BCG-exposed #NMIBC (HG Ta/T1/CIS)
✅ 6 & 12 mo CR: 94% & 81%
✅ 6, 12 & 18 mo HG-RFS: 97%, 85%, 76%
✅ 2 Gr AEs (UTI, pneumonitis). No Gr 4,5 AEs
Phase 3 trial vs BCG will follow #SUO24 #BladderCancer @oncodaily.bsky.social
✅ 6 & 12 mo CR: 94% & 81%
✅ 6, 12 & 18 mo HG-RFS: 97%, 85%, 76%
✅ 2 Gr AEs (UTI, pneumonitis). No Gr 4,5 AEs
Phase 3 trial vs BCG will follow #SUO24 #BladderCancer @oncodaily.bsky.social